Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CD74_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CD74_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CD74_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CD74_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CD74_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CD74_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/CD74_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CD74_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CD74_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CD74_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CD74_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CD74_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CD74_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000151611 | Cervix | HSIL_HPV | prostaglandin biosynthetic process | 7/737 | 31/18723 | 1.64e-04 | 3.14e-03 | 7 |
GO:004645711 | Cervix | HSIL_HPV | prostanoid biosynthetic process | 7/737 | 31/18723 | 1.64e-04 | 3.14e-03 | 7 |
GO:004665111 | Cervix | HSIL_HPV | lymphocyte proliferation | 25/737 | 288/18723 | 1.93e-04 | 3.56e-03 | 25 |
GO:00465965 | Cervix | HSIL_HPV | regulation of viral entry into host cell | 8/737 | 42/18723 | 2.00e-04 | 3.64e-03 | 8 |
GO:004563913 | Cervix | HSIL_HPV | positive regulation of myeloid cell differentiation | 13/737 | 103/18723 | 2.00e-04 | 3.65e-03 | 13 |
GO:005092011 | Cervix | HSIL_HPV | regulation of chemotaxis | 21/737 | 223/18723 | 2.05e-04 | 3.70e-03 | 21 |
GO:003294311 | Cervix | HSIL_HPV | mononuclear cell proliferation | 25/737 | 291/18723 | 2.27e-04 | 4.03e-03 | 25 |
GO:004277114 | Cervix | HSIL_HPV | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 8/737 | 43/18723 | 2.37e-04 | 4.15e-03 | 8 |
GO:0002285 | Cervix | HSIL_HPV | lymphocyte activation involved in immune response | 19/737 | 194/18723 | 2.46e-04 | 4.27e-03 | 19 |
GO:001922111 | Cervix | HSIL_HPV | cytokine-mediated signaling pathway | 35/737 | 472/18723 | 2.64e-04 | 4.52e-03 | 35 |
GO:000276112 | Cervix | HSIL_HPV | regulation of myeloid leukocyte differentiation | 14/737 | 120/18723 | 2.67e-04 | 4.54e-03 | 14 |
GO:000645714 | Cervix | HSIL_HPV | protein folding | 20/737 | 212/18723 | 2.81e-04 | 4.69e-03 | 20 |
GO:190216514 | Cervix | HSIL_HPV | regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 5/737 | 16/18723 | 2.83e-04 | 4.69e-03 | 5 |
GO:007066512 | Cervix | HSIL_HPV | positive regulation of leukocyte proliferation | 16/737 | 150/18723 | 2.85e-04 | 4.71e-03 | 16 |
GO:199026612 | Cervix | HSIL_HPV | neutrophil migration | 14/737 | 122/18723 | 3.18e-04 | 5.15e-03 | 14 |
GO:0050864 | Cervix | HSIL_HPV | regulation of B cell activation | 19/737 | 198/18723 | 3.19e-04 | 5.15e-03 | 19 |
GO:00702061 | Cervix | HSIL_HPV | protein trimerization | 5/737 | 17/18723 | 3.89e-04 | 6.04e-03 | 5 |
GO:190222913 | Cervix | HSIL_HPV | regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 7/737 | 36/18723 | 4.38e-04 | 6.51e-03 | 7 |
GO:003367413 | Cervix | HSIL_HPV | positive regulation of kinase activity | 34/737 | 467/18723 | 4.49e-04 | 6.63e-03 | 34 |
GO:005092111 | Cervix | HSIL_HPV | positive regulation of chemotaxis | 15/737 | 141/18723 | 4.50e-04 | 6.63e-03 | 15 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0461218 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0461219 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0461223 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
hsa0461233 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
hsa0461242 | Breast | DCIS | Antigen processing and presentation | 25/846 | 78/8465 | 6.75e-08 | 1.28e-06 | 9.45e-07 | 25 |
hsa0461252 | Breast | DCIS | Antigen processing and presentation | 25/846 | 78/8465 | 6.75e-08 | 1.28e-06 | 9.45e-07 | 25 |
hsa0461220 | Cervix | CC | Antigen processing and presentation | 34/1267 | 78/8465 | 1.06e-09 | 2.14e-08 | 1.26e-08 | 34 |
hsa05152 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa04612110 | Cervix | CC | Antigen processing and presentation | 34/1267 | 78/8465 | 1.06e-09 | 2.14e-08 | 1.26e-08 | 34 |
hsa051521 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa0461224 | Cervix | HSIL_HPV | Antigen processing and presentation | 21/459 | 78/8465 | 5.10e-10 | 3.74e-08 | 3.02e-08 | 21 |
hsa051522 | Cervix | HSIL_HPV | Tuberculosis | 19/459 | 180/8465 | 3.99e-03 | 2.39e-02 | 1.93e-02 | 19 |
hsa0461234 | Cervix | HSIL_HPV | Antigen processing and presentation | 21/459 | 78/8465 | 5.10e-10 | 3.74e-08 | 3.02e-08 | 21 |
hsa051523 | Cervix | HSIL_HPV | Tuberculosis | 19/459 | 180/8465 | 3.99e-03 | 2.39e-02 | 1.93e-02 | 19 |
hsa0461243 | Cervix | N_HPV | Antigen processing and presentation | 20/349 | 78/8465 | 2.61e-11 | 1.42e-09 | 1.11e-09 | 20 |
hsa051524 | Cervix | N_HPV | Tuberculosis | 16/349 | 180/8465 | 3.05e-03 | 1.73e-02 | 1.35e-02 | 16 |
hsa0461253 | Cervix | N_HPV | Antigen processing and presentation | 20/349 | 78/8465 | 2.61e-11 | 1.42e-09 | 1.11e-09 | 20 |
hsa051525 | Cervix | N_HPV | Tuberculosis | 16/349 | 180/8465 | 3.05e-03 | 1.73e-02 | 1.35e-02 | 16 |
hsa04612 | Colorectum | SER | Antigen processing and presentation | 25/1580 | 78/8465 | 3.11e-03 | 2.11e-02 | 1.53e-02 | 25 |
hsa046121 | Colorectum | SER | Antigen processing and presentation | 25/1580 | 78/8465 | 3.11e-03 | 2.11e-02 | 1.53e-02 | 25 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
972 | CD74 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE | | MILATUZUMAB | MILATUZUMAB | |
972 | CD74 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE | antibody | 252166479 | MILATUZUMAB | |
972 | CD74 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE | antagonist | CHEMBL1743040 | MILATUZUMAB | |
972 | CD74 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE | | Milatuzumab | MILATUZUMAB | |
972 | CD74 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE | antibody | MILATUZUMAB | MILATUZUMAB | |